Cargando…

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

AIMS: Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19. METHODS: CORONADO is a nationwide observational study that included patients with diabetes hospitalised for...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalau, Jean-Daniel, Al-Salameh, Abdallah, Hadjadj, Samy, Goronflot, Thomas, Wiernsperger, Nicolas, Pichelin, Matthieu, Allix, Ingrid, Amadou, Coralie, Bourron, Olivier, Duriez, Thierry, Gautier, Jean-François, Dutour, Anne, Gonfroy, Céline, Gouet, Didier, Joubert, Michael, Julier, Ingrid, Larger, Etienne, Marchand, Lucien, Marre, Michel, Meyer, Laurent, Olivier, Frédérique, Prevost, Gaëtan, Quiniou, Pascale, Raffaitin-Cardin, Christelle, Roussel, Ronan, Saulnier, Pierre-Jean, Seret-Begue, Dominique, Thivolet, Charles, Vatier, Camille, Desailloud, Rachel, Wargny, Matthieu, Gourdy, Pierre, Cariou, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832745/
https://www.ncbi.nlm.nih.gov/pubmed/33309936
http://dx.doi.org/10.1016/j.diabet.2020.101216
_version_ 1783641904106176512
author Lalau, Jean-Daniel
Al-Salameh, Abdallah
Hadjadj, Samy
Goronflot, Thomas
Wiernsperger, Nicolas
Pichelin, Matthieu
Allix, Ingrid
Amadou, Coralie
Bourron, Olivier
Duriez, Thierry
Gautier, Jean-François
Dutour, Anne
Gonfroy, Céline
Gouet, Didier
Joubert, Michael
Julier, Ingrid
Larger, Etienne
Marchand, Lucien
Marre, Michel
Meyer, Laurent
Olivier, Frédérique
Prevost, Gaëtan
Quiniou, Pascale
Raffaitin-Cardin, Christelle
Roussel, Ronan
Saulnier, Pierre-Jean
Seret-Begue, Dominique
Thivolet, Charles
Vatier, Camille
Desailloud, Rachel
Wargny, Matthieu
Gourdy, Pierre
Cariou, Bertrand
author_facet Lalau, Jean-Daniel
Al-Salameh, Abdallah
Hadjadj, Samy
Goronflot, Thomas
Wiernsperger, Nicolas
Pichelin, Matthieu
Allix, Ingrid
Amadou, Coralie
Bourron, Olivier
Duriez, Thierry
Gautier, Jean-François
Dutour, Anne
Gonfroy, Céline
Gouet, Didier
Joubert, Michael
Julier, Ingrid
Larger, Etienne
Marchand, Lucien
Marre, Michel
Meyer, Laurent
Olivier, Frédérique
Prevost, Gaëtan
Quiniou, Pascale
Raffaitin-Cardin, Christelle
Roussel, Ronan
Saulnier, Pierre-Jean
Seret-Begue, Dominique
Thivolet, Charles
Vatier, Camille
Desailloud, Rachel
Wargny, Matthieu
Gourdy, Pierre
Cariou, Bertrand
author_sort Lalau, Jean-Daniel
collection PubMed
description AIMS: Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19. METHODS: CORONADO is a nationwide observational study that included patients with diabetes hospitalised for COVID-19 between March 10 and April 10, 2020 in 68 French centres. The primary outcome combined tracheal intubation and/or death within 7 days of admission. A Kaplan-Meier survival curve was reported for death up to day 28. The association between metformin use and outcomes was then estimated in a logistic regression analysis after applying a propensity score inverse probability of treatment weighting approach. RESULTS: Among the 2449 patients included, 1496 were metformin users and 953 were not. Compared with non-users, metformin users were younger with a lower prevalence of diabetic complications, but had more severe features of COVID-19 on admission. The primary endpoint occurred in 28.0% of metformin users (vs 29.0% in non-users, P =  0.6134) on day 7 and in 32.6% (vs 38.7%, P = 0.0023) on day 28. The mortality rate was lower in metformin users on day 7 (8.2 vs 16.1%, P <  0.0001) and on day 28 (16.0 vs 28.6%, P < 0.0001). After propensity score weighting was applied, the odds ratios for primary outcome and death (OR [95%CI], metformin users vs non-users) were 0.838 [0.649−1.082] and 0.688 [0.470−1.007] on day 7, then 0.783 [0.615−0.996] and 0.710 [0.537−0.938] on day 28, respectively. CONCLUSION: Metformin use appeared to be associated with a lower risk of death in patients with diabetes hospitalised for COVID-19.
format Online
Article
Text
id pubmed-7832745
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-78327452021-01-26 Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 Lalau, Jean-Daniel Al-Salameh, Abdallah Hadjadj, Samy Goronflot, Thomas Wiernsperger, Nicolas Pichelin, Matthieu Allix, Ingrid Amadou, Coralie Bourron, Olivier Duriez, Thierry Gautier, Jean-François Dutour, Anne Gonfroy, Céline Gouet, Didier Joubert, Michael Julier, Ingrid Larger, Etienne Marchand, Lucien Marre, Michel Meyer, Laurent Olivier, Frédérique Prevost, Gaëtan Quiniou, Pascale Raffaitin-Cardin, Christelle Roussel, Ronan Saulnier, Pierre-Jean Seret-Begue, Dominique Thivolet, Charles Vatier, Camille Desailloud, Rachel Wargny, Matthieu Gourdy, Pierre Cariou, Bertrand Diabetes Metab Original Article AIMS: Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19. METHODS: CORONADO is a nationwide observational study that included patients with diabetes hospitalised for COVID-19 between March 10 and April 10, 2020 in 68 French centres. The primary outcome combined tracheal intubation and/or death within 7 days of admission. A Kaplan-Meier survival curve was reported for death up to day 28. The association between metformin use and outcomes was then estimated in a logistic regression analysis after applying a propensity score inverse probability of treatment weighting approach. RESULTS: Among the 2449 patients included, 1496 were metformin users and 953 were not. Compared with non-users, metformin users were younger with a lower prevalence of diabetic complications, but had more severe features of COVID-19 on admission. The primary endpoint occurred in 28.0% of metformin users (vs 29.0% in non-users, P =  0.6134) on day 7 and in 32.6% (vs 38.7%, P = 0.0023) on day 28. The mortality rate was lower in metformin users on day 7 (8.2 vs 16.1%, P <  0.0001) and on day 28 (16.0 vs 28.6%, P < 0.0001). After propensity score weighting was applied, the odds ratios for primary outcome and death (OR [95%CI], metformin users vs non-users) were 0.838 [0.649−1.082] and 0.688 [0.470−1.007] on day 7, then 0.783 [0.615−0.996] and 0.710 [0.537−0.938] on day 28, respectively. CONCLUSION: Metformin use appeared to be associated with a lower risk of death in patients with diabetes hospitalised for COVID-19. Elsevier Masson SAS. 2021-09 2020-12-10 /pmc/articles/PMC7832745/ /pubmed/33309936 http://dx.doi.org/10.1016/j.diabet.2020.101216 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Lalau, Jean-Daniel
Al-Salameh, Abdallah
Hadjadj, Samy
Goronflot, Thomas
Wiernsperger, Nicolas
Pichelin, Matthieu
Allix, Ingrid
Amadou, Coralie
Bourron, Olivier
Duriez, Thierry
Gautier, Jean-François
Dutour, Anne
Gonfroy, Céline
Gouet, Didier
Joubert, Michael
Julier, Ingrid
Larger, Etienne
Marchand, Lucien
Marre, Michel
Meyer, Laurent
Olivier, Frédérique
Prevost, Gaëtan
Quiniou, Pascale
Raffaitin-Cardin, Christelle
Roussel, Ronan
Saulnier, Pierre-Jean
Seret-Begue, Dominique
Thivolet, Charles
Vatier, Camille
Desailloud, Rachel
Wargny, Matthieu
Gourdy, Pierre
Cariou, Bertrand
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
title Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
title_full Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
title_fullStr Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
title_full_unstemmed Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
title_short Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
title_sort metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832745/
https://www.ncbi.nlm.nih.gov/pubmed/33309936
http://dx.doi.org/10.1016/j.diabet.2020.101216
work_keys_str_mv AT lalaujeandaniel metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT alsalamehabdallah metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT hadjadjsamy metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT goronflotthomas metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT wiernspergernicolas metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT pichelinmatthieu metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT allixingrid metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT amadoucoralie metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT bourronolivier metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT duriezthierry metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT gautierjeanfrancois metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT dutouranne metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT gonfroyceline metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT gouetdidier metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT joubertmichael metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT julieringrid metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT largeretienne metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT marchandlucien metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT marremichel metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT meyerlaurent metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT olivierfrederique metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT prevostgaetan metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT quinioupascale metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT raffaitincardinchristelle metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT rousselronan metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT saulnierpierrejean metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT seretbeguedominique metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT thivoletcharles metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT vatiercamille metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT desailloudrachel metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT wargnymatthieu metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT gourdypierre metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT carioubertrand metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19
AT metforminuseisassociatedwithareducedriskofmortalityinpatientswithdiabeteshospitalisedforcovid19